Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T, CTL, and DC Vaccine Combination for B-ALL
NCT05262673Phase 1Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA, Trivirus-specific cytotoxic T-lymphocytes and WT1/hTERT/Survivin-loaded dendritic cell vaccine in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoints: Safety of infusion at 1 year and Clinical response at 1 year. Started Jun 2026; status: terminated.
02
Drugs
CART-BCMATrivirus-specific cytotoxic T-lymphocytesWT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05262673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262673.